176 related articles for article (PubMed ID: 37936709)
61. Kinetics of humoral immune response over 17 months of COVID-19 pandemic in a large cohort of healthcare workers in Spain: the ProHEpiC-19 study.
Violán C; Torán-Monserrat P; Quirant B; Lamonja-Vicente N; Carrasco-Ribelles LA; Chacón C; Manresa-Dominguez JM; Ramos-Roure F; Dacosta-Aguayo R; Palacios-Fernández C; Roso-Llorach A; Pujol A; Ouchi D; Monteagudo M; Montero-Alia P; Garcia-Sierra R; Arméstar F; Doladé M; Prat N; Bonet JM; Clotet B; Blanco I; Boigues-Pons M; Moreno-Millán N; Prado JG; Cáceres EMM;
BMC Infect Dis; 2022 Sep; 22(1):721. PubMed ID: 36057544
[TBL] [Abstract][Full Text] [Related]
62. Acute and long-term immune responses to SARS-CoV-2 infection in unvaccinated children and young adults with inborn errors of immunity.
García-García A; Fortuny C; Fumadó V; Jordan I; Ruiz-López L; González-Navarro EA; Egri N; Esteve-Solé A; Luo Y; Vlagea A; Cabedo MM; Launes C; Soler A; Codina A; Juan M; Pascal M; Deyà-Martínez A; Alsina L
Front Immunol; 2023; 14():1084630. PubMed ID: 36742319
[TBL] [Abstract][Full Text] [Related]
63. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
64. Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection.
Gilboa M; Regev-Yochay G; Mandelboim M; Indenbaum V; Asraf K; Fluss R; Amit S; Mendelson E; Doolman R; Afek A; Freedman LS; Kreiss Y; Lustig Y
JAMA Netw Open; 2022 Sep; 5(9):e2231778. PubMed ID: 36107426
[TBL] [Abstract][Full Text] [Related]
65. Longitudinal Change of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies in Patients with Coronavirus Disease 2019.
Zhang G; Nie S; Zhang Z; Zhang Z
J Infect Dis; 2020 Jun; 222(2):183-188. PubMed ID: 32358956
[TBL] [Abstract][Full Text] [Related]
66. Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies.
Boekel L; Stalman EW; Wieske L; Hooijberg F; van Dam KPJ; Besten YR; Kummer LYL; Steenhuis M; van Kempen ZLE; Killestein J; Volkers AG; Tas SW; van der Kooi AJ; Raaphorst J; Löwenberg M; Takkenberg RB; D'Haens GRAM; Spuls PI; Bekkenk MW; Musters AH; Post NF; Bosma AL; Hilhorst ML; Vegting Y; Bemelman FJ; Voskuyl AE; Broens B; Parra Sanchez A; van Els CACM; de Wit J; Rutgers A; de Leeuw K; Horváth B; Verschuuren JJGM; Ruiter AM; van Ouwerkerk L; van der Woude D; Allaart CF; Teng YKO; van Paassen P; Busch MH; Jallah PBP; Brusse E; van Doorn PA; Baars AE; Hijnen DJ; Schreurs CRG; van der Pol WL; Goedee HS; Vogelzang EH; Leeuw M; Atiqi S; van Vollenhoven R; Gerritsen M; van der Horst-Bruinsma IE; Lems WF; Nurmohamed MT; Boers M; Keijzer S; Keijser J; van de Sandt C; Boogaard A; Cristianawati O; Ten Brinke A; Verstegen NJM; Zwinderman KAH; van Ham SM; Rispens T; Kuijpers TW; Wolbink G; Eftimov F;
Lancet Rheumatol; 2022 Jun; 4(6):e417-e429. PubMed ID: 35527808
[TBL] [Abstract][Full Text] [Related]
67. [Change in serum IgG antibody during the recovery stage of Omicron variant infection in children: an analysis of 110 cases].
Zhang PP; Guo YT; Chu YQ; Ji QI; Lian Y; Li W; Yao LN
Zhongguo Dang Dai Er Ke Za Zhi; 2022 Jul; 24(7):736-741. PubMed ID: 35894186
[TBL] [Abstract][Full Text] [Related]
68. [Monitoring of anti-SARS-CoV-2 IgG antibody immune responses in two cohorts of Hungarian healthcare workers following infection or immunization].
Gervain J; Szabóné Bartha K; Bakiné Hodovánszky E; Kadlecsik L; Herczeg R; Gyenesei A; Simon J
Orv Hetil; 2022 Mar; 163(12):455-462. PubMed ID: 35306478
[TBL] [Abstract][Full Text] [Related]
69. Characteristics of lymphocyte subsets and cytokine profiles of patients with COVID-19.
Pan P; Du X; Zhou Q; Cui Y; Deng X; Liu C; Hu Z; Chen J; Yu X; Shi W
Virol J; 2022 Mar; 19(1):57. PubMed ID: 35346253
[TBL] [Abstract][Full Text] [Related]
70. Pediatric population (aged 3-11 years) received primary inactivated SARS-CoV-2 vaccination prior to infection exhibiting robust humoral immune response following infected with Omicron variant: a study conducted in Beijing.
Li J; Li J; Dai S; Dang L; Wang L; Cao L; Chen X; Wang Y; Ge M; Liu W; Song Q; Xu W; Ma L
Front Immunol; 2023; 14():1269665. PubMed ID: 37828994
[TBL] [Abstract][Full Text] [Related]
71. Quantitative Analysis of SARS-CoV-2 Antibody Levels in Cancer Patients Post Three Doses of Immunization and Prior to Breakthrough COVID-19 Infections.
Macrae K; Martinez-Cajas J; Bessai K; Abdulhamed A; Gong Y
Curr Oncol; 2022 Sep; 29(10):7059-7071. PubMed ID: 36290831
[TBL] [Abstract][Full Text] [Related]
72. Assessment of neutralizing antibody responses after natural SARS-CoV-2 infection and vaccination in congolese individuals.
Batchi-Bouyou AL; Djontu JC; Vouvoungui JC; Mfoutou Mapanguy CC; Lobaloba Ingoba L; Mougany JS; Boumpoutou KR; Diafouka-Kietela S; Ampa R; Ntoumi F
BMC Infect Dis; 2022 Jul; 22(1):610. PubMed ID: 35831798
[TBL] [Abstract][Full Text] [Related]
73. Effect of COVID-19 Vaccination on the Levels of SARS-CoV-2 Neutralizing Antibodies in COVID-19 Naive, Hybrid, and Breakthrough SARS-CoV-2 Recovered Indian Individuals.
Deepika G; Adarsh S; Sadhana Y; Srihitha M; Veeraiah N; Reddy DN
J Lab Physicians; 2023 Sep; 15(3):377-382. PubMed ID: 37564232
[No Abstract] [Full Text] [Related]
74. Omicron neutralizing antibody response following booster vaccination compared with breakthrough infection.
Curlin ME; Bates TA; Guzman G; Schoen D; McBride SK; Carpenter SD; Tafesse FG
Med; 2022 Dec; 3(12):827-837.e3. PubMed ID: 36198311
[TBL] [Abstract][Full Text] [Related]
75. Long-Term Course of Humoral and Cellular Immune Responses in Outpatients After SARS-CoV-2 Infection.
Schiffner J; Backhaus I; Rimmele J; Schulz S; Möhlenkamp T; Klemens JM; Zapf D; Solbach W; Mischnik A
Front Public Health; 2021; 9():732787. PubMed ID: 34646805
[TBL] [Abstract][Full Text] [Related]
76. Preliminary Analysis of B- and T-Cell Responses to SARS-CoV-2.
Zhang LX; Miao SY; Qin ZH; Wu JP; Chen HY; Sun HB; Xie Y; Du YQ; Shen J
Mol Diagn Ther; 2020 Oct; 24(5):601-609. PubMed ID: 32710269
[TBL] [Abstract][Full Text] [Related]
77. Preexisting immunity restricts mucosal antibody recognition of SARS-CoV-2 and Fc profiles during breakthrough infections.
Selva KJ; Ramanathan P; Haycroft ER; Reynaldi A; Cromer D; Tan CW; Wang LF; Wines BD; Hogarth PM; Downie LE; Davis SK; Purcell RA; Kent HE; Juno JA; Wheatley AK; Davenport MP; Kent SJ; Chung AW
JCI Insight; 2023 Sep; 8(18):. PubMed ID: 37737263
[TBL] [Abstract][Full Text] [Related]
78. Cellular and humoral responses after second and third SARS-CoV-2 vaccinations in patients with autoimmune diseases treated with rituximab: specific T cell immunity remains longer and plays a protective role against SARS-CoV-2 reinfections.
Egri N; Calderón H; Martinez R; Vazquez M; Gómez-Caverzaschi V; Pascal M; Araújo O; Juan M; González-Navarro EA; Hernández-Rodríguez J
Front Immunol; 2023; 14():1146841. PubMed ID: 37180097
[TBL] [Abstract][Full Text] [Related]
79. [Humoral immunity against SARS-CoV-2 in workers of social health care centers of Castilla y León after vaccination with the BNT162b2 mRNA vaccine from Pfizer/Biontech.].
Casas Fischer R
Rev Esp Salud Publica; 2021 Oct; 95():. PubMed ID: 34690347
[TBL] [Abstract][Full Text] [Related]
80. Augmented humoral and cellular immunity against severe acute respiratory syndrome coronavirus 2 after breakthrough infection in kidney transplant recipients who received 3 doses of coronavirus disease 2019 vaccine.
Yang J; Lee KW; Baek JY; Bae S; Lee YH; Kim H; Huh K; Cho SY; Kang CI; Chung DR; Peck KR; Park JB; Kim SH; Kim TJ; Kim DM; Ko JH
Am J Transplant; 2023 Apr; 23(4):565-572. PubMed ID: 36739177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
